journal article·2025-06Open access

Dual‐Functional Hafnium Oxide Nanoplatform Combining High‐Z Radiosensitization With Bcl‐2 Gene Silencing for Enhanced Cancer Radiotherapy

Seungyong Shin, Ga‐Hyun Bae, Jun‐Hyeok Han, Ha Eun Shin, Joo Dong Park, Seunghyo Ko, Eun‐Young Koh, Jieun Han, Su Chul Han, Jason Joon Bock Lee, Dong‐Hyun Kim, Heerim Nam, Wooram Park

Advanced Healthcare Materials· Volume 14· Issue 15

Abstract

Abstract The efficacy of radiotherapy is often limited by insufficient radiosensitization and tumor radioresistance. This study reports a dual‐functional hafnium oxide nanoplatform that combines high‐Z radiosensitization with Bcl‐2 gene silencing for enhanced cancer radiotherapy. The nanoplatform is developed by surface modification of hafnium oxide nanoparticles with polyethyleneimine, enabling efficient siRNA delivery while maintaining inherent high‐Z radiosensitizing properties. Comprehensive physicochemical characterization confirmed the successful surface modification and stable siRNA complexation. Upon radiation exposure, the nanoplatform enhanced reactive oxygen species generation and DNA damage while simultaneously delivering Bcl‐2 siRNA to suppress radioresistance mechanisms. In vitro studies revealed significant enhancement of radiation‐induced cell death through synergistic effects of high‐Z radiosensitization and Bcl‐2 silencing, evidenced by increased γ‐H2AX expression and apoptotic cell population. In a murine colon cancer model, the nanoplatform achieved remarkable tumor growth inhibition (80%) when combined with radiotherapy while exhibiting favorable biocompatibility in major organs. Mechanistic studies confirmed effective Bcl‐2 downregulation and enhanced DNA damage in tumor tissues, validating this dual‐functional therapeutic approach. This study presents a promising strategy for improving radiotherapy outcomes through the simultaneous enhancement of radiosensitization and suppression of radioresistance, potentially advancing the field of cancer radiotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiation Therapy and Dosimetry · Nanoplatforms for cancer theranostics · Boron Compounds in Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Integrative Biotechnology College of Biotechnology and Bioengineering Sungkyunkwan University (SKKU) Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea

Department of MetaBioHealth Institute for Cross‐disciplinary Studies (ICS) SKKU Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea

Department of Radiation Oncology Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine Saemunan‐ro 29 Seoul 03181 Republic of Korea

Department of Radiology Feinberg School of Medicine Northwestern University Chicago 60611 USA

Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago IL 60611 USA

Department of Biomedical Engineering McCormick School of Engineering Northwestern University Evanston IL 60208 USA

Department of Biomedical Engineering University of Illinois Chicago IL 60607 USA

Funding

National Research Foundation of Korea

References (50)

Show source-provided references
1. 10.1038/nrclinonc.2012.20310.1038/nrclinonc.2012.203 ↗
2. 10.1016/S1470-2045(15)00222-310.1016/S1470-2045(15)00222-3 ↗
3. 10.1038/s41572-019-0064-510.1038/s41572-019-0064-5 ↗
4. 10.1056/NEJMoa120982510.1056/NEJMoa1209825 ↗
5. 10.1038/nrc395810.1038/nrc3958 ↗
6. 10.1016/j.canlet.2012.03.02410.1016/j.canlet.2012.03.024 ↗
7. 10.1002/btm2.1049810.1002/btm2.10498 ↗
8. 10.1016/j.tips.2017.11.00310.1016/j.tips.2017.11.003 ↗
9. 10.1186/s12951-020-00684-510.1186/s12951-020-00684-5 ↗
10. 10.1002/adma.20180224410.1002/adma.201802244 ↗
11. 10.1002/adma.20230222010.1002/adma.202302220 ↗
12. 10.1021/acsnano.3c0929310.1021/acsnano.3c09293 ↗
13. 10.1002/adma.20231413210.1002/adma.202314132 ↗
14. 10.1016/j.cej.2023.14208510.1016/j.cej.2023.142085 ↗
15. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗
16. 10.1016/j.ejca.2021.01.00710.1016/j.ejca.2021.01.007 ↗
17. 10.1158/1078-0432.CCR-13-322910.1158/1078-0432.CCR-13-3229 ↗
18. 10.3390/ijms16112599110.3390/ijms161125991 ↗
19. 10.1186/s13046-018-0758-710.1186/s13046-018-0758-7 ↗
20. 10.1016/j.stem.2012.12.01110.1016/j.stem.2012.12.011 ↗
21. 10.1038/s41575-019-0247-210.1038/s41575-019-0247-2 ↗
22. 10.1007/s13770-022-00453-510.1007/s13770-022-00453-5 ↗
23. 10.1007/s00432-017-2427-110.1007/s00432-017-2427-1 ↗
24. 10.1016/S0090-4295(98)00360-410.1016/S0090-4295(98)00360-4 ↗
25. 10.1038/sj.bjc.660264710.1038/sj.bjc.6602647 ↗
26. Azimian H. · Iran. J. Basic Med. Sci. · 2018 · 21 · 325
27. 10.1016/j.bbcan.2021.18856910.1016/j.bbcan.2021.188569 ↗
28. 10.1038/s41419-021-03971-710.1038/s41419-021-03971-7 ↗
29. 10.1158/1535-7163.MCT-06-036710.1158/1535-7163.MCT-06-0367 ↗
30. 10.1016/j.ejpb.2004.11.01110.1016/j.ejpb.2004.11.011 ↗
31. 10.1002/adhm.20120010910.1002/adhm.201200109 ↗
32. 10.1016/j.jconrel.2023.09.00110.1016/j.jconrel.2023.09.001 ↗
33. 10.1021/acsanm.0c0284510.1021/acsanm.0c02845 ↗
34. 10.1021/jacs.7b0132710.1021/jacs.7b01327 ↗
35. 10.1021/acsami.8b0959610.1021/acsami.8b09596 ↗
36. 10.1038/nprot.2007.24910.1038/nprot.2007.249 ↗
37. 10.1038/mt.2010.23310.1038/mt.2010.233 ↗
38. 10.1016/j.apsb.2024.03.00410.1016/j.apsb.2024.03.004 ↗
39. 10.1002/adfm.20231572110.1002/adfm.202315721 ↗
40. 10.1016/j.biomaterials.2014.06.02410.1016/j.biomaterials.2014.06.024 ↗
41. 10.1097/00022744-200112000-0000710.1097/00022744-200112000-00007 ↗
42. 10.1021/tx00026a01210.1021/tx00026a012 ↗
43. 10.1007/s00441000018810.1007/s004410000188 ↗
44. 10.1038/leu.2010.610.1038/leu.2010.6 ↗
45. 10.1038/nprot.2006.33910.1038/nprot.2006.339 ↗
46. E.Miller Cancer Cell Culture: Methods Protocols2004 191.10.1016/j.jconrel.2004.06.002 ↗
47. 10.1038/s41598-021-93964-510.1038/s41598-021-93964-5 ↗
48. 10.4103/0971-6203.15224910.4103/0971-6203.152249 ↗
49. 10.1007/978-1-61779-860-3_510.1007/978-1-61779-860-3_5 ↗
50. 10.1038/nrclinonc.2015.12010.1038/nrclinonc.2015.120 ↗